Dean Schorno
Director of Finance/CFO bei RIGEL PHARMACEUTICALS, INC.
Vermögen: 596 279 $ am 31.03.2024
Profil
Dean L.
Schorno is the Chief Financial Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. He previously worked as the Chief Financial Officer & Head-Investor Relations at Genomic Health, Inc. from 2011 to 2014, the Chief Financial Officer & Head-Operations at 23andMe, Inc. from 2015 to 2018, and the Chief Financial Officer at Adaptive Biotechnologies Corp.
in 2014 to 2015.
Schorno has a graduate degree from Golden Gate University and an undergraduate degree from the University of California, Berkeley.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.02.2024 | 402 891 ( 0,23% ) | 596 279 $ | 31.03.2024 |
Aktive Positionen von Dean Schorno
| Unternehmen | Position | Beginn |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Director of Finance/CFO | 29.05.2018 |
Ehemalige bekannte Positionen von Dean Schorno
| Unternehmen | Position | Ende |
|---|---|---|
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Director of Finance/CFO | 01.05.2018 |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director of Finance/CFO | 10.08.2015 |
| GENOMIC HEALTH, INC. | Director of Finance/CFO | 01.07.2014 |
Ausbildung von Dean Schorno
| Golden Gate University | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology 23andMe, Inc. provides genetic information using DNA analysis technologies and web-based interactive tools. It enables individuals to gain deeper insights into personal ancestry, genealogy, and inherited traits. The company was founded by Linda Avey, Paul L. Cusenza and Anne E. Wojcicki in 2006 and is headquartered in Sunnyvale, CA. | Health Technology |
